Literature DB >> 7667607

Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL).

T Bjøro1, L Mørkrid, R Wergeland, A Turter, A Kvistborg, T Sand, P Torjesen.   

Abstract

Of 605 hyperprolactinaemic sera (prolactin > 1000 mU l-1 determined with PRL DELFIA, Wallac) in the routine diagnostic (PRL was measured in 10,737 sera) 26% had an increased amount of PRL with molecular weight (MW) = 150-170 kD (150-170 kD PRL or bigbig PRL). In a series of serum samples from 660 healthy subjects, only one female with hyperprolactinaemia due to increased 150-170 kD PRL was found. The 150-170 kD PRL constituted less than 1% of the total PRL found in 11 patients with prolactinoma (macroprolactinoma, PRL 8800-500,000 mU l-1). When determined with five different commercially available immunometric assays, the PRL values in the sera with large amounts of 150-170 kD were increased in all sera in four of five assays, although they varied widely. The clinical implications of hyperprolactinaemia due to increased 150-170 kD PRL are still uncertain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667607     DOI: 10.3109/00365519509089606

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  12 in total

1.  Three cases of macroprolactinaemia.

Authors:  A O Olukoga; T L Dornan; J W Kane
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

Review 2.  ACP best practice no 170. Investigation of infertility with the emphasis on laboratory testing and with reference to radiological imaging.

Authors:  C Williams; T Giannopoulos; E A Sherriff
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays.

Authors:  B Cavaco; S Prazeres; M A Santos; L G Sobrinho; V Leite
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

4.  Clinical and radiological findings in macroprolactinemia.

Authors:  Serhat Isik; Dilek Berker; Yasemin Ates Tutuncu; Ufuk Ozuguz; Ferhat Gokay; Gonul Erden; Hatice Nursun Ozcan; Ferit Kerim Kucukler; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2011-12-21       Impact factor: 3.633

5.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

Review 6.  Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.

Authors:  Mohamed Saleem; Helen Martin; Penelope Coates
Journal:  Clin Biochem Rev       Date:  2018-02

7.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

8.  Hyperprolactinemia as a prognostic factor for menstrual disorders in female adolescents with advanced chronic kidney disease.

Authors:  Juana Serret-Montaya; Jessie N Zurita-Cruz; Miguel A Villasís-Keever; Alejandra Aguilar-Kitsu; Claudia Del Carmen Zepeda-Martinez; Irving Cruz-Anleu; Beatriz C Hernández-Hernández; Sara R Alonso-Flores; Leticia Manuel-Apolinar; Leticia Damasio-Santana; Abigail Hernandez-Cabezza; José C Romo-Vázquez
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

9.  Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease.

Authors:  Krzysztof C Lewandowski; Danuta Gąsior-Perczak; Aldona Kowalska; Andrzej Lewiński
Journal:  Thyroid Res       Date:  2012-12-17

Review 10.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.